TITLE

LIPONEX PROVIDES CLINICAL TRIAL UPDATE

PUB. DATE
September 2006
SOURCE
Worldwide Biotech;Sep2006, Vol. 18 Issue 9, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article presents an update on the preparations of biopharmaceutical company Liponex Inc. for Phase I/II clinical trial of its lead compound CRD5 for the treatment of dyslipidemia and heart disease. The bulk active pharmaceutical ingredient from contract manufacturer has been received by the company and quality testing and analysis has also been completed. The coverage of the trial is detailed.
ACCESSION #
22045061

 

Related Articles

  • Johnson & Johnson: Natrecor safety ripe for reexamination.  // PharmaWatch: Monthly Review;Jun2005, Vol. 4 Issue 6, p15 

    The article reports on the study that Nesiritide may have an increased risk of death after treatment for acutely decompensated heart failure. Although Johnson & Johnson, which manufactures nesiritide, has rightly pointed out that further clinical trials will done about the drug, the Journal of...

  • Grant Budgeting and Negotiating in India and China. Jankosky, Jena; Ying Jiang; Farwell, Ted // Applied Clinical Trials;Nov2007, Vol. 16 Issue 11, p56 

    The article discusses the effects of a rapidly developing market for clinical trials, namely in China and India, for researchers with less understanding and experience with cultural issues. China and India are burgeoning regions for the pharmaceutical industry and represent what some have called...

  • Nesiritide for outpatient treatment of heart failure. Bauer, Jered B.; Randazzo, Michael A. // American Journal of Health-System Pharmacy;12/15/2005, Vol. 62 Issue 24, p2639 

    The article presents a study on the outpatient use of nesiritide to minimize patient admission suffering from chronic heart failure in the U.S. A statistical report on the cost of medication for the treatment of heart failure is presented. Several clinical trials have found nesiritide to be safe...

  • Abbott Initiates Clinical Trial to Evaluate Absorb.  // Biotech Equipment Update;Jan2012, Vol. 20 Issue 1, p2 

    The article reports on the start of Abbott Laboratories Inc.'s ABSORB II randomized, controlled, and multi-center clinical trial that evaluates the safety, efficacy, and performance of Absorb bioresorbable vascular scaffold (BVS) in the U.S. The trial will test approximately 500 patients with...

  • Adjunctive treatment with eplerenone reduced 30 day all cause mortality in acute myocardial infarction. Pitt, B.; White, H.; Nicolau, J. // Evidence Based Medicine;Feb2006, Vol. 11 Issue 1, p14 

    The article reports on a study to determine whether adjunctive treatment with eplerenone can decrease morbidity and mortality better than placebo in patients with acute myocardial infarction (AMI) with left ventricular systolic dysfunction (LVSD) and heart failure. A randomized placebo...

  • Clinical brief.  // New Zealand Doctor;6/2/2004, p21 

    Reports on a research which tested a cardiac resynchronization therapy device for heart failure patients, which was published in the 2004 issue of "New England Journal of Medicine." Classification of clinical trial patients; Implications of the study's findings for heart failure treatment.

  • Clinical trials of antiarrhythmic therapies and optimizing health care resource deployment: the need for a paradigm shift. Saksena, Sanjeev // Journal of Interventional Cardiac Electrophysiology;Jan2012, Vol. 33 Issue 1, p1 

    The author reflects on the proliferation of randomized clinical trials (RCTs) of antiarrhythmic therapies and the optimization of health care resource deployment. He suggests the significance of RCTs in evidence-based medicine and practice guidelines in cardiac arrhythmias. He discusses the...

  • Polypharmacy and comorbidity in heart failure. Masoudi, Frederick A.; Krumholz, Harlan M. // BMJ: British Medical Journal (International Edition);9/6/2003, Vol. 327 Issue 7414, p513 

    Editorial. Comments on the complexity of care of patients with heart failure who suffer from other illnesses as well. Polypharmacotherapy inevitable in patients with heart failure and multiple comorbidities; Lack of data on this issue a result of studies excluding older patients with or...

  • A systematic review of the mediating role of knowledge, self-efficacy and self-care behaviour in telehealth patients with heart failure. Ciere, Yvette; Cartwright, Martin; Newman, Stanton P. // Journal of Telemedicine & Telecare;Oct2012, Vol. 18 Issue 7, p384 

    We conducted a systematic review of controlled trials and pre-post studies to examine whether the putative benefits of telehealth, notably, improvements in clinical outcomes and quality of life, are mediated by increases in knowledge, self-efficacy and self-care behaviour in patients with heart...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics